{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T03:41:12Z","timestamp":1793677272637,"version":"4.5.1"},"reference-count":32,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Clinician Scientist Fellowship"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Immune checkpoint inhibitor therapy (ICI) has greatly changed cancer therapy in recent years. The main side effects are immune-related adverse events (irAEs) that can affect any organ system. With the widespread use of ICIs, even rare irAEs, like acute kidney injury due to ICI-induced nephritis (ICI-AKI), have become a more common complication. Methods: All ICI-treated patients who underwent a kidney biopsy for AKI at a single academic center between January 2020 and December 2023 were analyzed. Results: We identified twelve cases of biopsy-proven ICI-AKI. The median follow up was 11.5 months. All cases showed acute interstitial nephritis (AIN) on the biopsy. Melanoma was the most common cancer, and dual-checkpoint inhibition with Ipilimumab and Nivolumab was the most common regimen. Extrarenal irAEs were present in only 25% of cases. Two-thirds had concomitant medication with proton pump inhibitors (PPIs). Only four patients completely recovered their kidney function, and one patient remained on kidney replacement therapy. Conclusions: AIN is a common cause of AKI in ICI-treated cancer patients. Although they respond well to steroid treatment, full restitution of kidney function occurs in less than half of the subjects. As ICIs are increasingly used in cancer management, more research on the prevention and treatment of ICI-associated AKI is needed.<\/jats:p>","DOI":"10.3390\/jcm14093231","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T11:38:06Z","timestamp":1746531486000},"page":"3231","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Immune Checkpoint Inhibitor-Associated Acute Kidney Injury: A Single-Center Experience of Biopsy-Proven Cases"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-4444-164X","authenticated-orcid":false,"given":"Andreas","family":"Kommer","sequence":"first","affiliation":[{"name":"Department of Internal Medicine I, University Medical Center of Johannes Gutenberg University, 55131 Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Stortz","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, University Medical Center of Johannes Gutenberg University, 55131 Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6351-3706","authenticated-orcid":false,"given":"Daniel","family":"Kraus","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, University Medical Center of Johannes Gutenberg University, 55131 Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7344-8381","authenticated-orcid":false,"given":"Julia","family":"Weinmann-Menke","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, University Medical Center of Johannes Gutenberg University, 55131 Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41573-021-00345-8","article-title":"The foundations of immune checkpoint blockade and the ipilimumab approval decennial","volume":"21","author":"Korman","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41416-018-0294-4","article-title":"PD-Loma: A cancer entity with a shared sensitivity to the PD-1\/PD-L1 pathway blockade","volume":"120","author":"Hirsch","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Haslam, A., Gill, J., and Prasad, V. (2020). Estimation of the Percentage of US Patients With Cancer Who Are Eligible for Immune Checkpoint Inhibitor Drugs. JAMA Netw. Open, 3.","DOI":"10.1001\/jamanetworkopen.2020.0423"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Xu, C., Chen, Y.-P., Du, X.-J., Liu, J.-Q., Huang, C.-L., Chen, L., Zhou, G.-Q., Li, W.-F., Mao, Y.-P., and Hsu, C. (2018). Comparative safety of immune checkpoint inhibitors in cancer: Systematic review and network meta-analysis. BMJ, 363.","DOI":"10.1136\/bmj.k4226"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: Epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.xkme.2021.08.008","article-title":"Immune Checkpoint Inhibitors and Kidney Toxicity: Advances in Diagnosis and Management","volume":"3","author":"Seethapathy","year":"2021","journal-title":"Kidney Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1681\/ASN.2019070676","article-title":"Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study","volume":"31","author":"Cortazar","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ekir.2020.10.002","article-title":"A Systematic Review of Immune Checkpoint Inhibitor-Associated Glomerular Disease","volume":"6","author":"Kitchlu","year":"2021","journal-title":"Kidney Int. Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.2215\/CJN.00990119","article-title":"The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors","volume":"14","author":"Seethapathy","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Koks, M.S., Ocak, G., Suelmann, B.B.M., Hulsbergen-Veelken, C.A.R., Haitjema, S., Vianen, M.E., Verhaar, M.C., Kaasjager, K.A.H., and Khairoun, M. (2021). Immune checkpoint inhibitor-associated acute kidney injury and mortality: An observational study. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0252978"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Baker, M.L., Yamamoto, Y., Perazella, M.A., Dizman, N., Shirali, A.C., Hafez, N., Weinstein, J., Simonov, M., Testani, J.M., and Kluger, H.M. (2022). Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy. J. Immunother. Cancer, 10.","DOI":"10.1136\/jitc-2021-004421"},{"key":"ref_12","first-page":"887","article-title":"Acute kidney injury as a risk factor for mortality in oncological patients receiving checkpoint inhibitors","volume":"37","author":"Bolufer","year":"2022","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1093\/ndt\/gfab346","article-title":"Development and external validation of a diagnostic model for biopsy-proven acute interstitial nephritis using electronic health record data","volume":"37","author":"Moledina","year":"2022","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10157-020-02008-1","article-title":"Incidence and risk factors of acute kidney injury, and its effect on mortality among Japanese patients receiving immune check point inhibitors: A single-center observational study","volume":"25","author":"Shimamura","year":"2021","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1177\/10781552231171078","article-title":"Cohort study on immune checkpoint inhibitor-associated acute kidney injury: Incidence, risk factors, and management strategies","volume":"30","author":"Panich","year":"2023","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Elghawy, O., Patel, R., Barsouk, A., Puthumana, J., Xu, J., Sussman, J., Horton, B., and Kaur, V. (2024). Diagnosis, management, and outcomes of immune checkpoint inhibitor induced acute interstitial nephritis: A single-center experience. J. Oncol. Pharm. Pract., 10781552241252627.","DOI":"10.1177\/10781552241252627"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"16","DOI":"10.34067\/KID.0000152019","article-title":"Acute Interstitial Nephritis and Checkpoint Inhibitor Therapy: Single Center Experience of Management and Drug Rechallenge","volume":"1","author":"Manohar","year":"2020","journal-title":"Kidney360"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/j.ajkd.2021.05.012","article-title":"Incidence and Predictors of CKD and Estimated GFR Decline in Patients Receiving Immune Checkpoint Inhibitors","volume":"79","author":"Chute","year":"2022","journal-title":"Am. J. Kidney Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update","volume":"39","author":"Schneider","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Gupta, S., Short, S.A.P., Sise, M.E., Prosek, J.M., Madhavan, S.M., Soler, M.J., Ostermann, M., Herrmann, S.M., Abudayyeh, A., and Anand, S. (2021). Acute kidney injury in patients treated with immune checkpoint inhibitors. J. Immunother. Cancer, 9.","DOI":"10.1136\/jitc-2021-003467"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.kint.2024.09.017","article-title":"Diagnosis and management of immune checkpoint inhibitor-associated nephrotoxicity: A position statement from the American Society of Onco-nephrology","volume":"107","author":"Herrmann","year":"2025","journal-title":"Kidney Int."},{"key":"ref_22","first-page":"622","article-title":"Adverse renal effects of check-point inhibitors (ICI) in cancer patients: Recommendations of the Onco-nephrology Working Group of the Spanish Society of Nephrology","volume":"43","author":"Alonso","year":"2023","journal-title":"Nefrol. Engl. Ed."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.ekir.2021.01.013","article-title":"Biomarkers, Clinical Features, and Rechallenge for Immune Checkpoint Inhibitor Renal Immune-Related Adverse Events","volume":"6","author":"Isik","year":"2021","journal-title":"Kidney Int. Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.ekir.2022.11.020","article-title":"Cytokines and Immune Cell Phenotype in Acute Kidney Injury Associated With Immune Checkpoint Inhibitors","volume":"8","author":"Farooqui","year":"2023","journal-title":"Kidney Int. Rep."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Moledina, D.G., Wilson, F.P., Pober, J.S., Perazella, M.A., Singh, N., Luciano, R.L., Obeid, W., Lin, H., Kuperman, M., and Moeckel, G.W. (2019). Urine TNF-alpha and IL-9 for clinical diagnosis of acute interstitial nephritis. JCI Insight, 4.","DOI":"10.1172\/jci.insight.127456"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Sise, M.E., Wang, Q., Seethapathy, H., Moreno, D., Harden, D., Smith, R.N., Rosales, I.A., Colvin, R.B., Chute, S., and Cornell, L.D. (2023). Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis. J. Immunother. Cancer, 11.","DOI":"10.1136\/jitc-2022-006222"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Moledina, D.G., Obeid, W., Smith, R.N., Rosales, I., Sise, M.E., Moeckel, G., Kashgarian, M., Kuperman, M., Campbell, K.N., and Lefferts, S. (2023). Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis. J. Clin. Investig., 133.","DOI":"10.1172\/JCI168950"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Singh, S., Long, J.P., Tchakarov, A., Dong, Y., Yee, C., and Lin, J.S. (2022). Tertiary lymphoid structure signatures are associated with immune checkpoint inhibitor related acute interstitial nephritis. JCI Insight.","DOI":"10.1172\/jci.insight.165108"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1053\/j.ajkd.2016.02.057","article-title":"Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients","volume":"68","author":"Shirali","year":"2016","journal-title":"Am. J. Kidney Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejca.2021.01.005","article-title":"Renal adverse effects of immune checkpoints inhibitors in clinical practice: ImmuNoTox study","volume":"147","author":"Espi","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1007\/s10637-020-01039-5","article-title":"Nephrotoxicity in patients with solid tumors treated with anti-PD-1\/PD-L1 monoclonal antibodies: A systematic review and meta-analysis","volume":"39","author":"Li","year":"2021","journal-title":"Investig. New Drugs"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.ekir.2019.06.001","article-title":"Anti-PD-1 Immunotherapy May Induce Interstitial Nephritis With Increased Tubular Epithelial Expression of PD-L1","volume":"4","author":"Cassol","year":"2019","journal-title":"Kidney Int. Rep."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/9\/3231\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:28:13Z","timestamp":1760030893000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/9\/3231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,6]]},"references-count":32,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["jcm14093231"],"URL":"https:\/\/doi.org\/10.3390\/jcm14093231","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,6]]}}}